Highest-materiality recent filing
Integra LifeSciences shareholders approve 3.55M share increase to equity incentive plan
Shareholders approved Amendment No. 3 to increase shares available under the plan by 3,550,000 to 24,250,000 total shares.
Integra Q1 2026: Adj. EPS $0.54 vs $0.41; raises FY adj. EPS guidance to $2.40-$2.50
Q1 revenue $391.9M (+2.4% reported; +1.3% organic). GAAP net loss $(4.6)M vs $(25.3)M prior year.
Integra LifeSciences Appoints Stuart Essig as President and CEO, Replacing Mojdeh Poul
Stuart Essig appointed President and CEO effective May 1, 2026; he also remains Chairman of the Board.
Integra LifeSciences amends $150M A/R facility, extends termination to April 2029
Scheduled termination date of $150M accounts receivable securitization facility extended to April 10, 2029.
Q4 2025 revenues $434.9M (-1.7% reported, -2.5% organic YoY); GAAP EPS $(0.02) vs $0.25; adj EPS $0.83 vs $0.97.
Integra adopts CIC severance program; CFO gets 2x multiple
Program effective Jan 1, 2026; covers Lea Knight (CFO), Robert Davis, Michael McBreen, Harvinder Singh.
Integra LifeSciences Q3 revenue $402.1M, adjusted EPS $0.54; cuts full-year guidance
Q3 reported revenues $402.1M, +5.6% YoY; organic growth 5.0%.
Integra LifeSciences Q2 GAAP EPS –$6.31 on $511M goodwill impairment; adj EPS $0.45 vs $0.63 YoY
Revenue $415.6M, down 0.6% reported and 1.4% organic YoY; Codman Specialty Surgical flat, Tissue Tech down 4.1%.
Integra Lifesciences amends credit agreement, raises max leverage ratio to 5.00x through mid-2026
Maximum permitted consolidated total leverage ratio raised to 5.00:1 for fiscal quarters ending Mar 2025 through Jun 2026.
Stockholders approved Amendment No. 2 to increase shares under equity plan by 2.2M, to 20.7M total.
Integra LifeSciences Q1 2025: Adj EPS $0.41 vs $0.55 YoY; organic revenue down 3.5%
Revenue of $382.7M up 3.7% reported but down 3.5% organic; GAAP net loss $(0.33)/share vs $(0.04).
Q4 2024: rev $442.6M (+11.5% rep, +3.5% org); adj EPS $0.97 vs $0.89; GAAP EPS $0.25 flat YoY.
Integra LifeSciences receives FDA warning letter for quality system violations at three facilities
FDA warning letter dated Dec 19, 2024, for quality system issues at Mansfield, MA; Plainsboro, NJ; Princeton, NJ facilities.
Program covers named executives including CFO Lea Knight, with severance multiple of 2x (1.5x for others) base salary plus target bonus.
Integra LifeSciences names Mojdeh Poul as President & CEO effective Jan 6, 2025
Mojdeh Poul appointed President & CEO, effective January 6, 2025, succeeding Jan De Witte.
Integra Q3 revenue down 0.4%, GAAP EPS loss; lowers FY2024 guidance; appoints new CEO
Revenue $380.8M, down 0.4% reported and 8.6% organic; GAAP EPS $(0.14) vs $0.24, adjusted EPS $0.41 vs $0.76.
Integra LifeSciences Q2: GAAP loss $0.16/sh, adj EPS $0.63; cuts FY2024 guidance on compliance holds
GAAP net loss $12.4M (-$0.16 diluted) vs prior year income $4.2M ($0.05). Adjusted EPS $0.63 vs $0.71.
Integra LifeSciences enters $50M accelerated share repurchase with Morgan Stanley
Signed ASR agreement on May 16, 2024 with Morgan Stanley & Co. LLC.
Board authorizes $50M share repurchase program; repurchases expected to begin Q2 2024 subject to market conditions.
Q1 revenues $368.9M (-3.1%); GAAP EPS $(0.04); adj. EPS $0.55; guidance raised on Acclarent
Q1 revenues $368.9M (-3.1% reported, -2.5% organic; +1.6% organic ex-Boston); GAAP net loss $3.3M ($(0.04)/share) vs net income $24.2M ($0.29) prior year.
On May 5, 2026, Integra LifeSciences Holdings Corporation (the "Company") announced the appointment of Dr. Stuart M. Essig to serve as its President and Chief Executive Officer, effective as of May 1, 2026 (the "Start Date").
Dr. Essig succeeds Mojdeh Poul, who is departing from her role as the Company's President and Chief Executive Officer and as a member of the Company's Board of Directors (the "Board") effective as of the end of the day on April 30, 2026 (the "Separation Date").
Dr. Essig succeeds Mojdeh Poul, who is departing from her role as the Company's President and Chief Executive Officer and as a member of the Company's Board of Directors (the "Board") effective as of the end of the day on April 30, 2026 (the "Separation Date").
On November 4, 2024, Integra LifeSciences Holdings Corporation (the “Company”) announced the appointment of Mojdeh Poul to serve as its President and Chief Executive Officer.
Max materiality 0.85 · Median 0.70 · Most common event earnings